12+

Check Treatment Eligibility

Enter your patient's mutations below

TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data.

Eligible

Please check to see if the mutation was entered correctly.

Results

Learn how to enter 2 or more mutations

>5,000 PATIENTS WHO HAVE
INITIATED TRIKAFTA were not on
a CFTR modulator at time
of prescription2

>4,000 PATIENTS WERE NAÏVE to CFTR modulators2

>1,000 PATIENTS DISCONTINUED
another CFTR modulator before
initiating treatment with TRIKAFTA2b,c

aTRIKAFTA initiation information is based on data from prescriptions received by specialty pharmacies between October 20, 2019, and May 29, 2020. These data do not include all patients and do not include patient genotypes.2
bNeither comparisons with other treatments nor conclusions regarding efficacy should be made.2
cDiscontinued patients were off a CFTR modulator for a period of time—at least 90 days—before starting on TRIKAFTA.